Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Expects WUXI BIO (02269.HK) PPQ Project Pipeline to Continue Supporting 2026 Growth; Rating Kept at Overweight
Recommend 9 Positive 10 Negative 4 |
||||
|
||||
|
WUXI BIO (02269.HK) released a document to be presented at the 44th JPM Healthcare Conference tomorrow (14th) listing a number of ongoing projects that exceeded JPMorgan's expectations, according to JPMorgan's research report. Several operational highlights are viewed positively, including the Company's successful achievement of strong revenue and profit growth in 2025, the completion of 28 process performance qualifications (PPQs) last year and plans to complete 34 this year. These data points are expected to support the Company's continued growth this year. The broker remained confident in the Company's ability to gain market share in the overall biologics outsourcing market, and secure more commercial projects. JPMorgan believed that its advanced biomanufacturing technology platform enables it to effectively capture future growth opportunities in demand for advanced full-scale continuous bioprocessing. Therefore, the broker kept rating at Overweight, with a target price of $37. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
